Outcomes of children following a first hospitalization for dilated cardiomyopathy

Circ Heart Fail. 2012 Jul 1;5(4):437-43. doi: 10.1161/CIRCHEARTFAILURE.111.964510. Epub 2012 May 8.

Abstract

Background: We hypothesized that children with dilated cardiomyopathy who require hospital admission are at increased risk for death or transplantation during their first hospitalization and in the first year that follows. We also assessed the value of routine data collected during that time to predict death or the need for transplantation prior to discharge and within 1 year of admission.

Methods and results: We conducted a retrospective review of 83 pediatric patients with dilated cardiomyopathy whose initial hospitalization fell between 2004 and 2009. The mean age at hospitalization was 7 years. The majority of patients demonstrated moderate or severe left ventricular dysfunction on initial echocardiogram (80%) and/or the need for intravenous inotropes within 7 days of hospital admission (69%). Five patients (6%) died, and 15 (18%) were transplanted in the initial hospitalization. At 1 year, 11/71 (15%) had died, and 27/71 (38%) were transplanted. The overall freedom from death, transplantation, or rehospitalization at 1 year following admission was 21%. Fractional shortening, left ventricular ejection fraction, serum cholesterol, uric acid, mixed venous saturation, and atrial filling pressures were all predictive of death or transplantation during the initial hospitalization. Left ventricular ejection fraction was predictive of death or transplantation at 1 year.

Conclusions: The first hospitalization for dilated cardiomyopathy marks a period of high risk for clinical decline, end stage heart failure, and the need for cardiac transplantation. Echocardiographic function and hemodynamic and serum measurements may aid in predicting outcomes. Despite medical management, most patients will be rehospitalized and/or require cardiac transplantation within 1 year of admission.

MeSH terms

  • Adolescent
  • Age Factors
  • Atrial Function
  • Biomarkers / blood
  • Cardiomyopathy, Dilated / diagnosis
  • Cardiomyopathy, Dilated / mortality
  • Cardiomyopathy, Dilated / physiopathology
  • Cardiomyopathy, Dilated / therapy*
  • Cardiotonic Agents / therapeutic use*
  • Chi-Square Distribution
  • Child
  • Child, Preschool
  • Cholesterol / blood
  • Decision Support Techniques
  • Female
  • Heart Transplantation* / mortality
  • Hospitalization* / statistics & numerical data
  • Humans
  • Infant
  • Infant, Newborn
  • Kaplan-Meier Estimate
  • Logistic Models
  • Male
  • Multivariate Analysis
  • Myocardial Contraction
  • Patient Readmission
  • Prognosis
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Stroke Volume
  • Time Factors
  • Uric Acid / blood
  • Ventricular Dysfunction, Left / physiopathology
  • Ventricular Dysfunction, Left / therapy
  • Ventricular Function, Left
  • Young Adult

Substances

  • Biomarkers
  • Cardiotonic Agents
  • Uric Acid
  • Cholesterol